Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs

Journal of Clinical Investigation

Volumn 127, Issue 1, 2017, Pages 269-279

  Cheng, Liang ^a   Ma, Jianping ^b   Li, Jingyun ^b   Li, Dan ^a,c   Li, Guangming ^a   Li, Feng ^a   Zhang, Qing ^a,d   Yu, Haisheng ^b   Yasui, Fumihiko ^a   Ye, Chaobaihui ^a   Tsao, Li Chung ^a   Hu, Zhiyuan ^a   Su, Lishan ^a,b,e   Zhang, Liguo ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

^c SICHUAN UNIVERSITY   (China)

^d XUZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA BETA INTERFERON RECEPTOR 1; BLOCKING ANTIBODY; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IMMUNOGLOBULIN G2A ANTIBODY; INTERFERON; MONOCLONAL ANTIBODY; RALTEGRAVIR; RECEPTOR ANTIBODY; RESIQUIMOD; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOID TISSUE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE I; MICE; MICE, MUTANT STRAINS; RECEPTOR, INTERFERON ALPHA-BETA; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION;

EID: 85008395064     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90745     Document Type: Article

References (52)

1. Zuniga EI, Hahm B, Oldstone MB. Type I interferon during viral infections: multiple triggers for a multifunctional mediator. Curr Top Microbiol Immunol. 2007;316:337-357.
2. Schoggins JW, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481-485.
3. Wilson EB, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340(6129):202-207.
4. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207-211.
5. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol. 2015;13(7):403-413.
6. Bosinger SE, Utay NS. Type I interferon: understanding its role in HIV pathogenesis and therapy. Curr HIV/AIDS Rep. 2015;12(1):41-53.
7. Stacey AR, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83(8):3719-3733.
8. Hardy GA, et al. Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One. 2013;8(2):e56527.
9. Lavender KJ, et al. Interferon α subtype-specific suppression of HIV-1 infection in vivo. J Virol. 2016;90(13):6001-6013.
10. Sandler NG, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511(7511):601-605.
11. Jacquelin B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119(12):3544-3555.
12. Bosinger SE, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest. 2009;119(12):3556-3572.
13. Harris LD, et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol. 2010;84(15):7886-7891.
14. Favre D, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5(2):e1000295.
15. + T-cells from HIV-1-infected individuals. PLoS Pathog. 2010;6(2):e1000781.
16. + T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol. 2007;81(7):3477-3486.
17. + T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol. 2008;82(4):1870-1883.
18. Azzoni L, et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013;207(2):213-222.
19. Sun H, et al. Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis. 2014;209(9):1315-1320.
20. Jiao YM, et al. Hepatitis C therapy with interferon- α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antiviral Res. 2015;118:118-122.
21. Morón-López S, et al. Short-term treatment with interferon alfa diminishes expression of HIV-1 and reduces CD4+ T-cell activation in patients coinfected with HIV and hepatitis C virus and receiving antiretroviral therapy. J Infect Dis. 2016;213(6):1008-1012.
22. Manion M, et al. Interferon-α administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012;7(1):e30306.
23. + T cells. J Infect Dis. 2011;204(12):1927-1935.
24. Dunham RM, et al. Discordance between peripheral and colonic markers of inflammation during suppressive ART. J Acquir Immune Defic Syndr. 2014;65(2):133-141.
25. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155.
26. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12(11):786-798.
27. Zhang L, Su L. HIV-1 immunopathogenesis in humanized mouse models. Cell Mol Immunol. 2012;9(3):237-244.
28. Li G, et al. Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice. PLoS Pathog. 2014;10(7):e1004291.
29. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One. 2013;8(10):e77780.
30. Halper-Stromberg A, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158(5):989-999.
31. -/- mouse. J Virol. 2012;86(1):114-120.
32. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr. 2011;56(2):118-124.
33. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.
34. Katlama C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109-2117.
35. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014;12(11):750-764.
36. Deng K, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517(7534):381-385.
37. Shan L, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36(3):491-501.
38. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169-174.
39. Siliciano RF. Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure. Nat Med. 2014;20(5):480-481.
40. Zhang Z, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS. 2013;27(8):1283-1293.
41. Levin D, et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci Signal. 2014;7(327):50.
42. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15(4):231-242.
43. Massanella M, et al. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment. Antivir Ther (Lond). 2010;15(3):333-342.
44. Zhang Z, et al. Plasmacytoid dendritic cells promote HIV-1-induced group 3 innate lymphoid cell depletion. J Clin Invest. 2015;125(9):3692-3703.
45. Lorenzo-Redondo R, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530(7588):51-56.
46. Tomescu C, Mavilio D, Montaner LJ. Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-α-activated NK cells requires NKp46 and NKG2D. AIDS. 2015;29(14):1767-1773.
47. Greenblatt MB, et al. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One. 2012;7(9):e44664.
48. Fukazawa Y, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med. 2015;21(2):132-139.
49. Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med. 2013;210(1):143-156.
50. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM. Infection of the SCID-hu mouse by HIV-1. Science. 1988;242(4886):1684-1686.
51. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108.
52. Laird GM, Rosenbloom DI, Lai J, Siliciano RF, Siliciano JD. Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. Methods Mol Biol. 2016;1354:239-253.